Actively Recruiting
The ctDNA-RECIST Trial Part One
Led by Karen-Lise Garm Spindler · Updated on 2025-05-01
167
Participants Needed
2
Research Sites
293 weeks
Total Duration
On this page
Sponsors
K
Karen-Lise Garm Spindler
Lead Sponsor
V
Vejle Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
A study investigating if analysis of circulating tumor DNA (ctDNA) can guide palliative treatment in patients with gastrointestinal cancer.
CONDITIONS
Official Title
The ctDNA-RECIST Trial Part One
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Incurable metastatic gastrointestinal cancer
- Indication for first or second-line systemic treatment
- Measurable disease according to RECIST v.1.1
- CT scan of chest and abdomen less than 30 days old at treatment start
- Age at least 18 years
- ECOG performance status 0-2
- Clinically eligible for systemic palliative treatment as decided by investigator
- Adequate bone marrow, liver, and kidney function for chemotherapy
- Use of anticonception for fertile women and male patients with fertile partners
- Written and verbal informed consent
You will not qualify if you...
- Incapacity, frailty, disability, or comorbidity incompatible with combination chemotherapy
- Other active cancer except non-melanoma skin cancer or cervical carcinoma in situ
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Aarhus University Hospital
Aarhus, Denmark, 8000
Actively Recruiting
2
Department pf Oncology, Vejle Hospital
Vejle, Denmark, 7100
Actively Recruiting
Research Team
K
Karen-Lise G Spindler, MD, Prof
CONTACT
T
Torben F Hansen, MD, Prof
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here